Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indivior Pharmaceuticals, Inc. filings document formal disclosures for a Nasdaq-listed specialty pharmaceutical company focused on buprenorphine-based treatments for opioid use disorder. Its 8-K reports cover operating results, Regulation FD presentations, material agreements, capital-structure matters, and financing events, including the 0.625% Convertible Senior Notes due 2031.
Indivior’s proxy materials describe shareholder voting matters, board and governance practices, executive compensation, and the company’s operating roadmap for SUBLOCADE growth. The filing record also includes common-stock registration details, financial disclosures tied to its OUD treatment business, share-repurchase activity, and registration-status matters.
Indivior Pharmaceuticals’ Chief Legal Officer Jeffrey W. Burris reported new equity awards. He acquired 26,897 shares of common stock on February 10, 2026 through a grant of restricted stock units with a stated value of $0 per share, bringing his direct holdings to 27,657 common shares.
He was also granted 104,300 performance stock units on February 9, 2026. These units relate to a conditional award originally granted on March 3, 2023, for 104,300 shares, with performance conditions certified on February 9, 2026 and vesting on March 3, 2026, subject to continued employment. The new RSUs vest in three equal annual installments beginning February 10, 2027.
Indivior Pharmaceuticals, Inc. Chief Scientific Officer Christian Heidbreder reported equity awards in the form of stock-based compensation. On February 10, 2026, he acquired, via grant, 33,622 restricted stock units of common stock at a price of $0 and now directly holds 190,762 common shares.
On February 9, 2026, he was also granted 132,565 performance stock units at a price of $0. These performance stock units relate to a conditional award whose performance conditions were certified on February 9, 2026 and are scheduled to vest on March 3, 2026, subject to continued employment. The RSUs vest in three equal annual installments beginning February 10, 2027.
Indivior Pharmaceuticals, Inc. reported that its Chief Commercial Officer, Barry Patrick A, acquired 31,380 shares of common stock on February 10, 2026 through a grant of restricted stock units. These RSUs vest in three equal annual installments starting on February 10, 2027, subject to his continued service with the company.
Indivior Pharmaceuticals, Inc.’s Chief Executive Officer and director Joseph Ciaffoni reported receiving a grant of 79,976 shares of common stock in the form of restricted stock units at a price of $0 per share. Following this equity award, he beneficially owns 135,976 common shares directly.
The RSUs vest in three equal annual installments starting on February 10, 2027, the first anniversary of the grant. Each unit represents the right to receive one share of common stock, contingent on his continued service with the company.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of 3,592,430.80 shares of Indivior Pharmaceuticals, Inc. common stock, representing 2.9% of the class as of the reported date.
The firms report shared voting power over 3,592,395.80 shares and shared dispositive power over 3,592,430.80 shares, with no sole voting or dispositive power. They state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Indivior Pharmaceuticals.
Indivior Pharmaceuticals, Inc. director receives equity grant. Director Kingsley Stuart A reported an award of 3,722 shares of common stock on January 26, 2026, recorded at a price of $0 per share as a stock-based grant rather than a purchase.
The grant is in the form of Restricted Stock Units, each representing one future share of common stock. These RSUs vest on the day immediately before the first annual stockholders’ meeting following the grant date, as long as the director continues to serve on that date. After this award, the director beneficially owns 4,642 shares directly.
Indivior Pharmaceuticals director David E. Wheadon reported a grant of 5,955 shares of common stock on January 26, 2026, reflected as an acquisition at a price of $0 per share. After this equity grant, he beneficially owned 20,350 shares in total.
The grant consists of restricted stock units (RSUs), each representing a right to receive one share of common stock. These RSUs vest on the day immediately before the first annual stockholder meeting following the grant date, contingent on his continued service to Indivior through that vesting date.
Indivior Pharmaceuticals director receives equity grant. Director Ryan Barbara was granted 3,722 shares of Indivior Pharmaceuticals, Inc. common stock on January 26, 2026 as a stock-based award at a price of $0 per share. After this grant, Barbara beneficially owns 5,685 common shares in total.
The award is in the form of restricted stock units (RSUs), each representing the right to receive one share of common stock. These RSUs vest on the day immediately before the first annual stockholders’ meeting following the grant date, contingent on Barbara’s continued service to the company through that vesting date.
Indivior Pharmaceuticals director Daniel A. Ninivaggi received an equity grant through restricted stock units. On 01/26/2026 he was awarded 3,722 RSUs, recorded at a price of $0 per unit, increasing his beneficial ownership to 20,645 shares of common stock held directly.
The RSUs each represent a right to receive one share of Indivior common stock. They vest on the day immediately before the first annual meeting of stockholders following the grant date, as long as he continues to serve the company through that vesting date.
Indivior Pharmaceuticals, Inc. director Mark Stejbach reported a grant of 3,722 shares of common stock in the form of Restricted Stock Units on January 26, 2026 at a price of $0 per share. Following this award, he beneficially owns 20,569 common shares in total.
Each RSU represents the right to receive one share of common stock and will vest on the day immediately before the first annual stockholders’ meeting after the grant date, as long as Stejbach continues serving the company through that vesting date.